Zobrazeno 1 - 10
of 3 605
pro vyhledávání: '"Astragaloside"'
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-12 (2024)
Abstract This study investigated the therapeutic effects of astragaloside IV (AST) on spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease (MJD), a neurodegenerative disorder. Human neuroblastoma SK-N-SH cells expressing mutant
Externí odkaz:
https://doaj.org/article/6c3f7f8be7bd4a0b84758276b51aa4a0
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-14 (2024)
Abstract Immune checkpoint inhibitors (ICIs) are effective agents for tumor immunotherapy. However, their clinical effectiveness is unsatisfactory due to off-target effects and a suppressive immune microenvironment. This study developed a nanodrug de
Externí odkaz:
https://doaj.org/article/190c095085bf45a0a868557c4eec096e
Publikováno v:
Journal of Traditional Chinese Medical Sciences, Vol 11, Iss 3, Pp 340-350 (2024)
Objective: To determine the main components of Astragalus membranaceus (Fisch.) Bge (A. membranaceus, Huang Qi), Astragaloside IV (AIV) and Astragalus polysaccharides (AP), to characterize their properties, evaluate their in vivo efficacy, and to ana
Externí odkaz:
https://doaj.org/article/025f576f73db4bb78e5179887cdaa1a2
Publikováno v:
Botanical Studies, Vol 65, Iss 1, Pp 1-7 (2024)
Abstract Background Astragaloside IV is a main medicinal active ingredient in Astragalus membranaceus Bge. var. mongholicus (Bge.) Hsiao, which is also the key biomarker of A. membranaceus quality. Ethylene has been well-documented to involve in seco
Externí odkaz:
https://doaj.org/article/5e67211f0dec403c92e9458f4e4676e1
Autor:
JinFang Hao, Xiaoyan Zhang, Ruixian Hu, Xiufeng Lu, Hui Wang, Yuanhong Li, Kai Cheng, Qingshan Li
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-17 (2024)
Abstract Background Astragaloside IV (AST-IV), as an effective active ingredient of Astragalus membranaceus (Fisch.) Bunge. It has been found that AST-IV inhibits the replication of dengue virus, hepatitis B virus, adenovirus, and coxsackievirus B3.
Externí odkaz:
https://doaj.org/article/e41b8acfc29148e3ba6d9fa07b20e082
Autor:
Yuanzhang Zhu, Fei Lu
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-13 (2024)
Abstract Background Astragaloside IV (AS-IV) is one of the basic components of Astragali radix, that has been shown to have preventive effects against various diseases, including cancers. This study aimed to explore the role of AS-IV in hepatocellula
Externí odkaz:
https://doaj.org/article/a83fa0736ad24dc2903a58c6c076495f
Autor:
Xiao Wang, Xinting Chen, Yuting Wang, Xinyu He, Lan Li, Xiaodan Wang, Yuting Huang, Guanwei Fan, Jingyu Ni
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundHeart failure with preserved ejection fraction (HFpEF) has grown to become the dominant form of heart failure worldwide. However, no unequivocally effective treatment for HFpEF has been identified in clinical trials. In this study, we repor
Externí odkaz:
https://doaj.org/article/bf96e4de8ec4410db026b8cf7405ea77
Publikováno v:
European Journal of Histochemistry, Vol 68, Iss 4 (2024)
Programmed cell death protein-1 (PD-1) inhibitors are increasingly utilized in the treatment of lung cancer (LC). Combination therapy has recently gained popularity in treating LC. This study aimed to assess the efficacy of combining Astragaloside IV
Externí odkaz:
https://doaj.org/article/eda13e9e2fd24675bd933b9c0a535e17
Autor:
Peizhao Du, Linghao Xu, Yuanqi Wang, Tiantian Jiao, Jing Cheng, Chunsheng Zhang, Md Sakibur Rahman Tapu, Jian Dai, Jiming Li
Publikováno v:
Heliyon, Vol 10, Iss 17, Pp e37019- (2024)
Astragaloside IV(AS-IV), the main active ingredient of Astragalus, has been used as a treatment for heart failure with favorable effects, but its molecular mechanism has not been fully elucidated. Network pharmacological analysis and molecular dockin
Externí odkaz:
https://doaj.org/article/ce105a7594a84275a13a0c2a6a3f1815
Autor:
Xinhui Zhang, Fan Zhang, Yan Li, Na Fan, Ke Zhao, Anding Zhang, Jiefang Kang, Yan Lin, Xiaochang Xue, Xun Jiang
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-17 (2024)
Abstract Background The specific pathogenesis of UC is still unclear, but it has been clear that defects in intestinal barrier function play an important role in it. There is a temporary lack of specific drugs for clinical treatment. Astragaloside IV
Externí odkaz:
https://doaj.org/article/fcc4ced7e6ef4d20ab3034e2291a4913